Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients listed for an ablation procedure for treatment of atrial fibrillation or flutter at TGH requiring sedation provided by an anesthetist~* Valid consent~Exclusion Criteria:~* Baseline HR \<40~* Baseline SBP \< 80mmHg~* Baseline SBP \> 180mmHg~* Second or third degree heart block unless pacemaker in situ~* Uncontrolled heart failure/severe LV dysfunction (Ejection fraction \< 40%)~* Severe hepatic dysfunction (Transaminases greater than 2 times the upper limit of normal)~* Renal dysfunction: estimated GFR \< 30ml/min, or requiring dialysis~* Allergy to any of the study drugs (dexmedetomidine, remifentanil, fentanyl, midazolam)~* Cognitive impairment precluding ability to tolerate sedation and comply with assessment methods~* Requirement for general anaesthetic for the procedure~* Pregnancy or breast feeding mothers~* Chronic use or addiction to opioids~* \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine Group (Type: EXPERIMENTAL): The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
- Remifentanil Group (Type: ACTIVE_COMPARATOR): Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)

Based on this trial design, predict the completion outcome and termination type (if applicable).